文献速递多重用药老年慢病共病管理

老年结直肠癌患者合并用药质量与化疗不良反应及生存的关联

Association of Comedication Quality With Chemotherapy-Related Adverse Drug Reactions and Survival in Older Colorectal Cancer Patients.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2022-01-01

该队列研究纳入3239例65岁及以上结直肠癌患者,用FORTA评分评估合并用药质量。总FORTA评分≥7分者5年总生存和CRC特异生存均更差,但未发现与化疗相关不良反应显著相关。

要点

  • 总FORTA评分≥7分与更差的5年总生存和CRC特异生存相关。
  • 潜在不适当用药和用药过度亚评分与生存差相关,用药不足无关联。
  • 未观察到合并用药质量与化疗相关不良反应的显著关联。

核心结论

  • 较差的总体合并用药质量与更差的5年总生存和结直肠癌特异生存显著相关。
  • 需要随机对照试验验证改善老年结直肠癌患者合并用药管理能否延长生存。

研究设计与样本

  • 队列研究,纳入3239例65岁及以上结直肠癌患者。
  • 生存分析纳入3239例,化疗相关不良反应分析纳入1209例。
  • 采用FORTA总分及用药过度、用药不足、潜在不适当用药三个亚评分评估合并用药质量。
  • 使用多变量Cox比例风险或logistic回归模型评估关联。

主要发现

  • 总FORTA评分≥7分 versus 0-1分,5年总生存的HR为1.83(95%CI 1.40-2.40)。
  • 总FORTA评分≥7分 versus 0-1分,5年CRC特异生存的HR为1.76(95%CI 1.22-2.52)。
  • 潜在不适当用药和用药过度亚评分与更差的5年总生存和CRC特异生存相关,用药不足亚评分无关联。
  • 未观察到总FORTA评分或潜在不适当用药评分与化疗相关不良反应的显著关联。
  • 关联在男性及直肠癌患者中较女性和结肠癌患者更强。

临床怎么用

  • 对老年结直肠癌患者应关注合并用药质量,尤其是潜在不适当用药和用药过度。
  • 改善合并用药管理可能有助于延长生存,但需随机对照试验证实。

局限性

  • 原文未系统报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence about the clinical relevance of appropriate comedication among older colorectal cancer (CRC) patients is sparse. METHODS: A cohort study was conducted with 3239 CRC patients aged 65 years and older. To assess comedication quality, we calculated the total Fit fOR The Aged (FORTA) score and its subscores for medication overuse, underuse, and potentially inappropriate medication use. Multivariable Cox proportional hazards or logistic regression models were performed to evaluate the association of comedication quality with up to 5-year overall survival, CRC-specific survival, and chemotherapy-related adverse drug reactions. RESULTS: Overall, 3239 and 1209 participants were included in analyses on survival and adverse drug reactions, respectively. The hazard ratios [95% confidence intervals] for the total FORTA score ≥ 7 versus 0-1 points were 1.83 [1.40-2.40] and 1.76 [1.22-2.52] for up to 5-year overall and CRC-specific survival, respectively. Worse up to 5-year overall survival and CRC-specific survival was also evident for FORTA subscores for potentially inappropriate medication use and overuse, whereas no association was observed for underuse. Although results for the total FORTA and potentially inappropriate medication score were much stronger among patients receiving chemotherapy, no significant associations with chemotherapy-related adverse drug reactions were observed. Moreover, associations were particularly strong among men and rectal cancer patients as compared to women and colon cancer patients. CONCLUSIONS: Poor total comedication quality was significantly associated with worse up to 5-year overall and CRC-specific survival. Randomized controlled trials are needed to test whether improved cancer comedication management in older CRC patients prolongs survival.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Chen LJ, Nguyen TNM, Laetsch DC, et al. Association of Comedication Quality With Chemotherapy-Related Adverse Drug Reactions and Survival in Older Colorectal Cancer Patients. J Gerontol A Biol Sci Med Sci. 2022. PMID: 34251458. doi:10.1093/gerona/glab198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。